Advances and Updates in the Management of MSI-H Colorectal Cancer: A
Closer Look at the Evolving Role of Immunotherapy
is a two-part webinar series
A continuing medical
education activity sponsored by NAMCP and AAMCN
This webinar series will provide critical updates on the advances in
the management of Colorectal Cancer
These are archives of live webinars held between February 24, 2021
to February 26, 2021
If you participated in any of the live webinars, you are not
eligible to claim credit from the archive of that webinar.
By clicking on each of the titles, you will be able to participate
in each part.
It is not required that you participate in all three or in order.
These activities are valid from March 1, 2021 to March 1, 2023
series is supported by an educational grant from
Merck Sharp & Dohme Corp.
This activity is intended for healthcare professionals practicing in managed
Instructions for CME/NCPD: Complete the pre-test,
listen to the audio and view the slides, complete the post test, complete the
evaluation form and hit submit. You will be asked to enter your name and email
address on the pre-test, evaluation and post-test. If you close your internet
browser without completing the post test, you will have ONE more opportunity to
complete. A score of 70% must be achieved on the post test to receive continuing
education credits. If you do not pass the post test after two attempts, you will
not be eligible to try again. Once you complete the evaluation form and score
70% or higher on your post test, you will automatically be given your
Colorectal cancer (CRC) is the development of cancer
from the colon or rectum, due to the abnormal growth of cells that have the
ability to invade or spread to other parts of the body. Excluding skin cancers,
CRC is the third most common cancer diagnosed in both men and women in the
United States. In 2021, it is expected that there will be 149,500 new cases of
colorectal cancer and 52,980 deaths. When discovered early, CRC is highly
treatable. However, when the disease has spread, treatment becomes much more
difficult. Fortunately, immunotherapy options have become available for patients
with metastatic CRC, particular in MSI-High disease, giving clinicians and
managed care professionals more options in managing this patient population.